GI-View Overview
GI-View is a medical device start-up specializing in the development of disposable endoscopes. GI-View's single-use colonoscope addresses the need for single-use endoscopes and helps alleviate patient concerns about disease transmission and endoscope hygiene. The disposable single-use colonoscope has no cleaning cost or risk of disease transmission. Its panoramic view enables visualization of polyps behind colonic folds. Hydrophilic coating significantly reduces the forces on the colonic wall. The ergonomic colonoscope requires minimal training and CAPEX investment.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
FDA approves GI View's disposable colonoscope
Israeli company GI View Ltd. has received FDA clearance for its Aer-O-Scope Colonoscope System, the first colonoscope to provide a 360� omni-directional visualization of the colon to detect polyps behind folds. The system has therapeutic access and two working channels for biopsies and polypectomies. The Aer-O-Scope is disposable and self-propelled, increasing patient safety and comfort. The company plans to introduce the system to the US market and conduct post-market studies. Colorectal cancer can be prevented by early detection and removal of polyps.
Customers
growth-positive
GI View Ltd. Receives FDA 510(k) Clearance for the New Aer-O-Scope® Disposable Colonoscope System with Working Channels for Therapeutic Intervention During Colorectal Cancer Screening
GI View Ltd. has received FDA 510(k) clearance for its new Aer-O-Scope Colonoscope System, a disposable colonoscope system with therapeutic access. The system has two working channels that enable therapeutic access using standard tools. The Aer-O-Scope is the first colonoscope to provide a 360° omni-directional visualization of the colon to detect polyps behind folds. It is designed to increase patient safety and comfort, as well as physician ease of use. The company plans to introduce the system to the US market and conduct post-market studies. GI View Ltd. is dedicated to advancing the efficiency, accuracy, and comfort of colorectal cancer screening. The company has received ISO certification for quality systems and has several patents granted and pending. Investors in the company include Israel HealthCare Ventures Ltd., Ziegler Meditech Equity Partners, Kemper Insurance, and private investors.
Customers
growth-positive
Israeli Gi View Colorectal Cancer Scope Gets FDA Approval
GI View Ltd., a developer of advanced GI screening systems, has received FDA 510(k) clearance for its flagship product, the Aer-O-Scope Colonoscope System. The system is a comprehensive and easy-to-use tool for colorectal cancer screening. The company plans to introduce the product in the U.S. in early 2016. Colorectal cancer is a significant cause of cancer death worldwide, and the Aer-O-Scope system aims to improve early detection and prevention. The system offers unique advantages such as 360° omni-directional visualization, increased patient safety, and ease of use. It is also single-use and disposable, eliminating the risk of disease transmission. The article does not mention any specific partners, customers, or investment/acquisition details.
Customers
growth-positive
FDA approves GI-View's 360° colonoscope
GI-View, a colonoscopy device company, has obtained FDA approval for its product after 11 years of challenges. The company plans to raise $20 million from new investors for marketing the device. GI-Views product aims to replace existing colonoscopy devices and offers a 360-degree omni-directional visualization displayed on a single screen. The company has already raised $42 million in funding, including $13 million from existing investors. GI-View intends to assemble a team for direct marketing of the device to clinics in the US.
Investment
growth-positive
Diagnostics co GI View raises $10m
GI View Ltd., a start-up specializing in early diagnosis of cancer in the large intestine, has raised $10 million in its third financing round. The round was led by Israel Healthcare Ventures Ltd., with participation from Delta Ventures and previous private investors. The company, founded in 2003, has developed a disposable, miniaturized, self-propelled, self-navigating endoscope for early diagnosis of precancerous tumors. The latest financing round was held after receiving offers from three leading US venture capital funds to invest $30 million, but the board rejected the offers due to the condition of taking the company out of Israel. The current investors decided to invest at a significantly higher company value than the previous round. GI View has made good progress and exceeded targets, justifying the high valuation.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $23M |
| Last funding | $13M |
| Stage | Mature |
| Rounds | 2 |
| Investors | 4 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.giview.com |
| Careers | Careers page |
Locations
Ha-Tidhar Street 5, Ra'anana, Israel
Photos & Videos
3 item(s)
